AGIO vs. CPRX, EVO, KROS, AMPH, GLPG, SNDX, NAMS, ARDX, DCPH, and AMRX
Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Catalyst Pharmaceuticals (CPRX), Evotec (EVO), Keros Therapeutics (KROS), Amphastar Pharmaceuticals (AMPH), Galapagos (GLPG), Syndax Pharmaceuticals (SNDX), NewAmsterdam Pharma (NAMS), Ardelyx (ARDX), Deciphera Pharmaceuticals (DCPH), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical preparations" industry.
Catalyst Pharmaceuticals (NASDAQ:CPRX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking.
Catalyst Pharmaceuticals has a net margin of 15.83% compared to Catalyst Pharmaceuticals' net margin of -1,199.26%. Agios Pharmaceuticals' return on equity of 25.08% beat Catalyst Pharmaceuticals' return on equity.
Catalyst Pharmaceuticals received 5 more outperform votes than Agios Pharmaceuticals when rated by MarketBeat users. Likewise, 74.31% of users gave Catalyst Pharmaceuticals an outperform vote while only 67.71% of users gave Agios Pharmaceuticals an outperform vote.
79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 11.0% of Catalyst Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Catalyst Pharmaceuticals has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
Catalyst Pharmaceuticals currently has a consensus target price of $26.71, suggesting a potential upside of 62.00%. Agios Pharmaceuticals has a consensus target price of $35.00, suggesting a potential upside of 1.92%. Given Agios Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Catalyst Pharmaceuticals is more favorable than Agios Pharmaceuticals.
Catalyst Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 3 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.97 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.
Summary
Catalyst Pharmaceuticals beats Agios Pharmaceuticals on 17 of the 18 factors compared between the two stocks.
Get Agios Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agios Pharmaceuticals Competitors List
Related Companies and Tools
